Stason Pharmaceuticals, Inc. 2024-03-13 Health moderate FDA
Health · FDA · Recall #FDA-D-0367-2024
Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b)… Recall
Issued March 13, 2024 · Stason Pharmaceuticals, Inc.
In March 2024, Stason Pharmaceuticals, Inc. recalled the Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b)…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Dissolution Specifications: results slightly under spec at at 9-months.
What you should do
- 1 Stop using Mercaptopurine Tablets, USP 50 mg, packaged in: a) 25-count bottle (NDC 69076-913-02), b)… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Stason Pharmaceuticals, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Stason Pharmaceuticals, Inc.
- Category
- Health
- Recall date
- March 13, 2024
- Units affected
- Not reported
- Sold at
- USA Nationwide
- Recall number
- FDA-D-0367-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- Stason Pharmaceuticals, Inc. has 1 recall in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.